Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024

Launched by MOHSEN POURAZIZI · Sep 30, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness and safety of two medications, cyclosporine 0.05% (known as Restasis) and Lifitgrast (called Xiidra), in helping patients feel better after a special eye surgery called photorefractive keratectomy (PRK). The researchers want to find out if these medications can reduce common eye problems like pain, redness, and inflammation that some people experience after the surgery. Participants will either receive one of the medications or a placebo (which is a type of artificial tears) before their surgery. Afterward, they will return to the clinic for check-ups at several points to see how they are healing.

To participate in this trial, individuals must be over 18 years old and have certain types of vision issues, like nearsightedness. They should not have had any recent eye surgeries, should not wear contact lenses for at least three weeks before the surgery, and should not have any active eye diseases or serious health conditions that could affect healing. Participants can expect to take the assigned medication about 30 minutes before their surgery and will need to attend follow-up visits for a week after the surgery to monitor their recovery. This trial is currently not recruiting participants, so please stay tuned for updates on when it will begin.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age above 18 years Myopia and myopic astigmatism The stability of the patients refraction over the past year Not using contact lenses at least 3 weeks before the operation Absence of history of KCN and any type of corneal ectasia in the patient himself or his first degree family No history of previous eye surgery and eye trauma Absence of active eye diseases, corneal dystrophy, retinal diseases, glaucoma, dry eyes of any degree.
• • Absence of systemic diseases that can potentially disrupt wound healing, including diabetes, vascular collagen diseases, and pregnancy.
• • Not taking inhaled or systemic steroids actively or within 3 months before the procedure Absence of anisometropia Not using any systemic and topical analgesia during the last week
• Exclusion Criteria:
• • The patients lack of consent to continue the study Failure to visit the patient for follow-up The occurrence of any complications during the patients surgery